Tahoe Therapeutics
PrivateLast Round
Series A
Aug 11, 2025
Est. Valuation
$120M
Total Funding Raised
$42M
Momentum Score
50 /100
Company Overview
Tahoe Therapeutics is a biotechnology company that is developing AI-powered models of the human cell to facilitate the design of better drugs for more patients, with an initial focus on cancer. The company's proprietary platform, Mosaic, generates large-scale, perturbative single-cell datasets to enable a new generation of biological foundation models. This technology aims to capture the context of disease and represent patient diversity at the first step of drug discovery. Following a $12 million seed round in 2022 and a rebrand from Vevo Therapeutics in April 2025, the company raised a $30 million Series A in August 2025 to expand its data generation capabilities. The company's goal is to accelerate the development of precision medicines and reduce clinical trial failure rates.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, ML Platforms, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tahoe Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Tahoe Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 11, 2025 | ||||
| Seed | Dec 8, 2022 |
Key People
Founding team and executive leadership
Tahoe Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Camford Capital | Seed |
| Mubadala Capital Ventures | Series A |
| Conviction Partners | Series A |
| General Catalyst | Series A, Seed |
| Mubadala Capital | Seed |
| Wing Venture Capital | Series A, Seed |
| Amplify Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
Announced Tahoe-x1 for rapid ML model iteration.
- Jan 1, 2026
Launched Tahoe-100M, a large-scale single-cell dataset for training foundation models.
Tahoe Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Tahoe Therapeutics's valuation, stock price, and market status.
